Buy Lasolvan solution 7.5 mg/ml vials 100 ml

Ambroxol

Brand Boehringer Ingelheim

In stock 1760 Items

Available since: 2019-09-19

Dosage form

pills
solution
syrup
effervescent pills
capsules

Brand & Manufacturer

Package Size

7.5 mg/ml vials 100 ml

$46.69

Quantity

All payments are SSL encrypted
Full Refund if you haven't received your order
International shipping to the USA, UK and Europe

Clinical Pharmacology

Lasolvan - secretomotor, secretolytic, expectorant.

Pharmacodynamics

Stimulates the serous cells of the glands of the mucous membrane of the bronchi, increases the content of mucous secretions and the release of surfactants (surfactant) in the alveoli and bronchi; normalizes the disturbed ratio of serous and mucous components of sputum. Activating hydrolytic enzymes and enhancing the release of lysosomes from Clara cells, reduces the viscosity of sputum. Increases the motor activity of cilia of the ciliated epithelium, increases mucociliary transport of sputum.

After ingestion, the action occurs after 30 minutes and lasts for 6–12 hours.

Pharmacokinetics

Absorption - high, C_max achieved in 2 hours (for pills, syrup), for solution for ingestion and inhalation - 0.5–3 hours; binding to plasma proteins - 80% (for pills, syrup), for oral solution and inhalation - 90%. Passes through the BBB, placental barrier, excreted in breast milk. The solution for ingestion and inhalation is rapidly distributed in the tissues, the highest concentration is achieved in the lungs.

Metabolized in the liver, forms dibromantranilic acid and glucuronic conjugates. Excreted by the kidneys - 90% in the form of water-soluble metabolites, 5% - unchanged. About 30% of the dose after oral administration is eliminated by means of the primary metabolism. T_1/2 - 1.3 hours, for a solution for ingestion and inhalation - 7–12 hours. There is no cumulative effect. The elimination half-life increases with severe chronic renal failure, but does not change with abnormal liver function.

Indications

Acute and chronic diseases of the respiratory tract, accompanied by the release of viscous sputum:

acute and chronic bronchitis;
pneumonia;
COPD;
bronchial asthma with sputum obstruction;
bronchiectasis.

Composition

2 ml of solution contains:

Active substance: ambroxol hydrochloride 15 mg;

Excipients: citric acid; disodium hydrogen phosphate dihydrate; sodium chloride; benzalkonium chloride; purified water.

Ambroxol is marketed under different brands and generic names, and comes in different dosage forms:

Brand name	Manufacturer	Country	Dosage form
Lasolvan	Boehringer Ingelheim	Austria	solution
Ambroxol	Obnovlenie PFK	Russia	pills
Ambroxol			solution
Ambroxol	Canonpharma	Russia	pills
Orvis Broncho			solution
Flavamed	Berlin-Chemie AG	Germany	solution
Flavamed	Berlin-Chemie AG	Germany	effervescent pills
Lasolvan	Boehringer Ingelheim	Austria	capsules
Lasolvan	Boehringer Ingelheim	Austria	syrup
Lasolvan	Boehringer Ingelheim	Austria	pills
Ambrohexal	Sandoz	Switzerland	syrup
Ambrobene	Teva	Israel	solution
Ambrobene	Teva	Israel	pills
Ambrobene	Teva	Israel	syrup
Ambrohexal	Sandoz	Switzerland	pills
Ambroxol	Ecolab	Russia	syrup
Ambrosan	PRO.MED.CS Praha a.s	Czech	pills
Halixol	Egis	Hungary	pills
Halixol	Egis	Hungary	syrup

No customer reviews for the moment.

Write your review

Dosage and Administration

Inside and inhalation.

For oral use. in the form of drops (1 ml = 25 drops), while eating, adding to tea, fruit juice, milk or water. Adults at the beginning of treatment - 4 ml 3 times a day, children over 6 years old - 2 ml (50 drops) 2-3 times a day, children from 2 to 6 years old - 1 ml (25 drops) 3 times a day , children under 2 years old - 1 ml (25 drops) 2 times a day.

InhalationAdults and children over 6 years old - 1-2 inhalations of 2-3 ml of solution daily, children under 6 years of age - 1-2 inhalations of 2 ml of solution daily.

Inhalation solution can be applied using any modern equipment for inhalation (except steam inhalers). The drug is mixed with saline, it can be diluted in a 1: 1 ratio to achieve optimal air moistening in the respirator. Since inhalation therapy, a deep breath can provoke cough tremors, inhalation should be carried out in normal breathing mode. Before inhalation, it is usually recommended to warm the inhalation solution to body temperature. Patients with bronchial asthma are advised to inhale after taking bronchodilators.

Adverse reactions

Allergic reactions: skin rash, urticaria, angioedema, in some cases - allergic contact dermatitis. Cases of acute severe reactions of the anaphylactic type (anaphylactic shock) have been extremely rarely reported.

Contraindications

With long-term use in high doses.- heartburn, gastralgia, nausea, vomiting.

Hypersensitivity; pregnancy (I term).

Carefully:

II – III trimester of pregnancy;
lactation period;
renal and / or liver failure.

Drug interactions

Compatible with drugs that inhibit generic activity.

Combined use with antitussive drugs leads to difficulty in sputum discharge on the background of cough reduction.

Increases bronchial secretion in amoxicillin, cefuroxime, erythromycin and doxycycline.

Pregnancy and Lactation

Preclinical trials and extensive clinical experience have not revealed undesirable effects of drug treatment during pregnancy. Nevertheless, it is necessary to follow the general rules of prescribing drugs, especially in the first trimester. Lasolvan^® penetrates into breast milk, but in therapeutic doses does not adversely affect the child.

If necessary, use Lasolvana^® in the II – III trimesters of pregnancy, the potential therapy for the mother and the possible risk to the fetus should be evaluated

Special instructions

It should not be combined with antitussive agents that impede the excretion of sputum.

The solution for oral administration and inhalation contains benzalkonium chloride. In patients with hyperactivity of the respiratory tract, this preservative may cause bronchospasm during inhalation.

Overdosage

Symptoms: possible - nausea, vomiting, diarrhea, dyspepsia, gastralgia.

Treatment: induction of vomiting, gastric lavage in the first 1-2 hours after taking the drug; reception of fat-containing products, symptomatic therapy.